Smithbridge Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.89M Buy
102,069
+3,079
+3% +$132K 0.67% 42
2026
Q1
$3.64M Sell
98,990
-100,198
-50% -$4.75M 0.54% 49
2025
Q4
$10.1M Buy
199,188
+104,709
+111% +$5.35M 0.87% 41
2025
Q3
$5.24M Buy
94,479
+2,845
+3% +$167K 0.76% 47
2025
Q2
$6.32M Buy
91,634
+3,103
+4% +$211K 1.11% 37
2025
Q1
$6.15M Buy
+88,531
New +$7.31M 1.14% 34
2024
Q3
$10.6M Sell
89,120
-3,207
-3% -$428K 1.83% 14
2024
Q2
$13.2M Sell
92,327
-166
-0.2% -$22K 2.74% 6
2024
Q1
$11.9M Sell
92,493
-3,128
-3% -$372K 2.45% 4
2023
Q4
$9.89M Sell
95,621
-1,657
-2% -$164K 2.25% 5
2023
Q3
$8.85M Sell
97,278
-2,908
-3% -$256K 2.19% 6
2023
Q2
$8.11M Sell
100,186
-2,780
-3% -$227K 1.9% 6
2023
Q1
$8.19M Sell
102,966
-4,434
-4% -$314K 2.06% 7
2022
Q4
$7.27M Sell
107,400
-752
-0.7% -$44.1K 1.93% 12
2022
Q3
$5.39M Buy
108,152
+974
+0.9% +$52.2K 2.21% 11
2022
Q2
$5.97M Sell
107,178
-662
-0.6% -$36.7K 2.31% 9
2022
Q1
$5.99M Sell
107,840
-610
-0.6% -$31.3K 1.98% 15
2021
Q4
$6.07M Sell
108,450
-4,848
-4% -$263K 1.85% 20
2021
Q3
$5.44M Sell
113,298
-4,054
-3% -$196K 1.8% 20
2021
Q2
$4.92M Buy
117,352
+1,064
+0.9% +$41.2K 1.6% 24
2021
Q1
$3.92M Buy
116,288
+2,140
+2% +$76.2K 1.68% 28
2020
Q4
$3.99M Sell
114,148
-1,210
-1% -$41.8K 1.84% 24
2020
Q3
$4M Sell
115,358
-340
-0.3% -$11.3K 2.07% 19
2020
Q2
$3.79M Sell
115,698
-10,200
-8% -$325K 2.11% 17
2020
Q1
$3.79M Sell
125,898
-13,290
-10% -$396K 2.53% 10
2019
Q4
$4.03M Sell
139,188
-14,250
-9% -$395K 2.08% 16
2019
Q3
$3.97M Buy
153,438
+1,590
+1% +$40.2K 2.23% 15
2019
Q2
$3.88M Sell
151,848
-180
-0.1% -$4.45K 2.24% 13
2019
Q1
$3.98M Buy
152,028
+2,150
+1% +$52.8K 2.39% 11
2018
Q4
$3.45M Buy
149,878
+3,192
+2% +$70.9K 2.42% 12
2018
Q3
$3.46M Buy
146,686
+1,040
+0.7% +$25.4K 2.08% 16
2018
Q2
$3.36M Buy
145,646
+980
+0.7% +$23.3K 2.15% 17
2018
Q1
$3.56M Sell
144,666
-2,468
-2% -$64.8K 2.36% 13
2017
Q4
$3.95M Buy
147,134
+5,560
+4% +$141K 2.49% 8
2017
Q3
$3.41M Sell
141,574
-4,540
-3% -$103K 2.4% 11
2017
Q2
$3.13M Buy
146,114
+30,800
+27% +$622K 2.58% 14
2017
Q1
$1.98M Sell
115,314
-3,560
-3% -$62K 1.73% 29
2016
Q4
$2.13M Buy
118,874
+21,440
+22% +$389K 1.88% 26
2016
Q3
$2.03M Buy
97,434
+26,626
+38% +$660K 1.81% 28
2016
Q2
$1.9M Sell
70,808
-100
-0.1% -$2.74K 1.77% 28
2016
Q1
$1.92M Sell
70,908
-4,800
-6% -$129K 1.79% 29
2015
Q4
$2.2M Sell
75,708
-300
-0.4% -$8.3K 2.02% 25
2015
Q3
$2.06M Sell
76,008
-3,200
-4% -$90.6K 1.95% 28
2015
Q2
$2.17M Sell
79,208
-5,500
-6% -$155K 1.82% 31
2015
Q1
$2.26M Sell
84,708
-100
-0.1% -$2.3K 1.87% 31
2014
Q4
$1.79M Sell
84,808
-300
-0.4% -$6.7K 1.47% 34
2014
Q3
$2.03M Sell
85,108
-202
-0.2% -$4.65K 1.7% 34
2014
Q2
$1.97M Sell
85,310
-3,300
-4% -$72.9K 1.66% 33
2014
Q1
$2.02M Sell
88,610
-5,230
-6% -$111K 1.84% 30
2013
Q4
$1.73M Sell
93,840
-5,500
-6% -$95.9K 1.59% 32
2013
Q3
$1.68M Sell
99,340
-500
-0.5% -$8.41K 1.59% 33
2013
Q2
$1.55M Buy
+99,840
New +$1.66M 1.56% 31

Other funds holding NVO

Smithbridge Asset Management's NVO Position: Q2 2026 in Review

Smithbridge Asset Management increased its Novo Nordisk (NVO) stake by 3.1% in Q2 2026, buying an estimated $132K and bringing the position to 102,069 shares worth $4.89M. The position accounts for 0.67% of the portfolio, ranked #42.

Smithbridge Asset Management first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.2M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Smithbridge Asset Management held 102,069 shares of Novo Nordisk worth $4.89M as of Q2 2026.
  • Smithbridge Asset Management bought 3,079 Novo Nordisk shares in Q2 2026, an estimated $132K.
  • Novo Nordisk made up 0.67% of Smithbridge Asset Management's portfolio in Q2 2026, its #42 holding.
  • Smithbridge Asset Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Smithbridge Asset Management's Novo Nordisk position peaked at $13.2M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Smithbridge Asset Management's 13F filing for Q2 2026, filed 20 Jul 2026.